The Kigali Amendment to the Montreal Protocol has guided the phasedown of HFAs across all industries, but until recently there has been an exemption for propellants used in pharmaceutical applications. However, regions are beginning to introduce their own targets, including removing the exemption for propellants used in pMDIs. This will impact the cost and availability of currently used propellants in the short term, and ultimately enforce a full transition to lower GWP alternatives.
Our Head of Drug Product Development, Ross Errington, discusses how the industry is approaching this change and the role CDMOs can play in our article in PMPS.
